Abstract
There is compelling evidence from seven RCTs that a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy given after optimal cytoreductive surgery significantly improves survival for women with FIGO stage III epithelial ovarian cancer. On the basis of this data, the US-NCI issued a Clinical Announcement in January 2006 recommending that women and their physicians consider such combined IV/IP chemotherapy where appropriate. Despite ongoing educational efforts, IP/IV regimens have not become the standard of care in many hospitals. Ongoing clinical research seeks to reduce the toxicity associated with IP chemotherapy while retaining efficacy and integrating new biological approaches to treatment. Copyrigth
| Translated title of the contribution | The combination of intravenous and intraperitoneal chemotherapy improves survival for women ovarian cancer |
|---|---|
| Original language | Spanish |
| Pages (from-to) | 323-325 |
| Number of pages | 3 |
| Journal | Salud(i)Ciencia |
| Volume | 18 |
| Issue number | 4 |
| State | Published - Jun 1 2011 |
| Externally published | Yes |
Keywords
- Chemotherapy
- Epithelial ovarian cancer
- Intraperitoneal chemotherapy
- Treatment
ASJC Scopus subject areas
- Medicine(all)